文献速递创伤与烧伤心脑血管急症重症综合管理与镇静镇痛

纤溶表型与创伤性脑损伤患者结局的关联

Association of fibrinolysis phenotype with patient outcomes following traumatic brain injury.
PubMed 文献 · J Trauma Acute Care Surg · 2023-09-13
一句话结论中重度TBI患者中纤溶关闭最常见,但纤溶表型与死亡率及其他主要并发症无关。

本研究基于一项安慰剂对照多中心临床试验数据,纳入747例≥15岁、GCS 3-12分、收缩压≥90 mmHg的TBI患者,院前随机接受安慰剂、1 g TXA弹丸+1 g TXA输注或2 g TXA弹丸。按入院LY30将纤溶表型分为关闭(≤0.8%)、生理性(0.9%-2.9%)和亢进(≥3%)。纤溶关闭最常见,与年龄、ISS和颅内出血相关;住院死亡率关闭和亢进均为15.2%,生理性为10.6%(p=0.49),6个月残疾评定量表、急性肾损伤、ARDS及多器官衰竭在各表型间均无差异。

要点

  • 747例中重度TBI患者中,纤溶关闭(LY30≤0.8%)是所有治疗组中最常见的表型。
  • 纤溶关闭与年龄更大、损伤严重度评分更高及颅内出血存在相关。
  • 住院死亡率纤溶关闭和亢进均为15.2%,生理性为10.6%(p=0.49),无统计学差异。
  • 6个月残疾评定量表、急性肾损伤、ARDS及多器官衰竭在各纤溶表型间均无差异。
  • 作者结论:TBI中纤溶表型与死亡率或其他主要并发症无关。

适用人群与场景

  • ≥15岁、GCS 3-12分、收缩压≥90 mmHg的TBI患者,取自安慰剂对照多中心临床试验,院前 setting 随机。

诊断标准与关键阈值

  • 纤溶表型按入院 clot lysis at 30 minutes(LY30)判定:纤溶关闭≤0.8%;生理性0.9%-2.9%;纤溶亢进≥3%。

处置流程与药物剂量

  • 院前随机分组:安慰剂弹丸/安慰剂输注(Placebo);1 g TXA弹丸/1 g TXA输注(bolus maintenance,BM);2 g TXA弹丸/安慰剂输注(bolus only,BO)。

研究设计与关键结果

  • 研究类型:安慰剂对照多中心临床试验数据二次分析;样本量747例;人群为≥15岁、GCS 3-12分、收缩压≥90 mmHg的TBI患者;干预为院前随机接受安慰剂、1 g TXA弹丸+1 g TXA输注或2 g TXA弹丸。
  • 纤溶关闭是所有治疗组中最常见的表型,并与年龄更大、损伤严重度评分更高及颅内出血存在相关。
  • 住院死亡率:纤溶关闭15.2%、纤溶亢进15.2%、生理性10.6%(p=0.49)。
  • 纤溶表型间在死亡率、6个月残疾评定量表、急性肾损伤、急性呼吸窘迫综合征或多器官衰竭方面均无差异。
  • 逻辑回归控制年龄、性别、穿透伤、损伤严重度评分、最大头AIS和TXA治疗组。

证据类型、等级与局限

  • 证据类型:安慰剂对照多中心临床试验数据的预后与流行病学分析;证据等级:Level IV。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:在TBI中,纤溶表型与死亡率或其他主要并发症无关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Impaired coagulation is associated with elevated risk of mortality in trauma patients. Prior studies have demonstrated increased mortality in patients with hyperfibrinolysis (HF) and fibrinolysis shutdown (SD). In addition, prior studies have demonstrated no effect of tranexamic acid (TXA) on fibrinolysis phenotypes. We examined the association of admission fibrinolysis phenotype with traumatic brain injury (TBI) patient outcomes.

METHODS: Data were extracted from a placebo-controlled multicenter clinical trial. Patients ≥15 years with TBI (Glasgow Coma Scale score, 3-12) and systolic blood pressure ≥90 mm Hg were randomized in the out-of-hospital setting to receive placebo bolus/placebo infusion (Placebo), 1 gram (g) TXA bolus/1 g TXA infusion (bolus maintenance [BM]); or 2 g TXA bolus/placebo infusion (bolus only [BO]). Fibrinolysis phenotypes on admission were determined by clot lysis at 30 minutes (LY30): SD, ≤0.8%; physiologic, 0.9% to 2.9%; HF, ≥3%. Logistic regression was used to control for age, sex, penetrating injury, Injury Severity Score, maximum head AIS, and TXA treatment group.

RESULTS: Seven hundred forty-seven patients met inclusion criteria. Fibrinolysis shutdown was the most common phenotype in all treatment groups and was associated with increased age, Injury Severity Score, and presence of intracranial hemorrhage (ICH). Inpatient mortality was 15.2% for SD and HF, and 10.6% for physiologic ( p = 0.49). No differences in mortality, disability rating scale at 6 months, acute kidney injury, acute respiratory distress syndrome, or multi-organ failure were noted between fibrinolysis phenotypes.

CONCLUSION: SD is the most common phenotype expressed in moderate to severe TBI. In TBI, there is no association between fibrinolysis phenotype and mortality or other major complications.

LEVEL OF EVIDENCE: Prognostic and Epidemiological; Level IV.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Durbin S, Brito A, Johnson A, et al. Association of fibrinolysis phenotype with patient outcomes following traumatic brain injury. J Trauma Acute Care Surg. 2023. PMID: 37700441. doi:10.1097/TA.0000000000004122

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。